FOXO4-DRI side effects and risks

Reported side effects

• Injection pain and swelling: Forum reports only; no reliable rate or dose response estimate., moderate. Persistent or worsening pain, redness or swelling needs assessment. (source)
• Low mood or disrupted sleep: One report after a 10 mg total course over three days., moderate. Stop exposure and seek care if symptoms persist or become severe. (source)
• More frequent bowel movements: One person reported this for three days; no clinical rate., mild (source)
• Possible harm to lung circulation: Mouse signal only; human incidence is unknown., serious. New breathlessness, chest pain or fainting needs urgent assessment. (source)
• Possible liver injury: Repeated dose mouse preprint; human incidence is unknown., serious. A clinician may check liver tests after exposure; no validated testing schedule exists. (source)
• Severe allergy or injection-related infection: General unregulated injection risks; no FOXO4 DRI specific rate., serious. Breathing problems need emergency care; hot, painful swelling needs same-day care. (source)

Stop and get help if

• Swollen tongue or throat, trouble breathing, or collapse after an injection.: Stop exposure and call emergency services now.
• Injection site becomes hot, painful or swollen, especially with fever.: Get same-day care. Call emergency services for confusion, fainting or fast breathing.
• New severe breathlessness, chest pain or fainting.: Stop exposure and seek emergency assessment.

Who should avoid it

• pregnant: Precaution: no pregnancy safety data or tested human dose.
• breastfeeding: Precaution: passage into milk and effects on infants are unknown.
• tryingToConceive: Precaution: mouse fertility findings do not establish safety around conception.
• under18: No pediatric dosing or safety study. Newborn-rat experiments do not establish child safety.
• activeCancer: Precaution: it changes p53 signaling. Human cancer-treatment effects are untested; involve the oncology team.
• cancerHistory: Long-term effects on cancer surveillance and recurrence are unknown.
• other: FOXO4-DRI worsened lung-vessel function in a susceptible mouse model; no human safety data.
• heartCondition: Lung-circulation harm in mice makes heart or lung disease a reason for clinician review.
• liverDisease: Repeated-dose liver toxicity appeared in a mouse preprint. No human dose adjustment is known.
• kidneyDisease: Mouse kidney benefits do not establish safety or dose adjustment in kidney disease.
• immunosuppressed: Unregulated injections can cause infection. Risks are higher with a weakened immune system.
• surgeryPlanned: No perioperative safety data. Tell the surgical team about exposure and any injection-site reaction.
• testedAthlete: Falls under the 2026 S0 rule for non-approved drugs; prohibited at all times.
• other: Previous severe allergy to the peptide, diluent or injected product.

Interactions

• Other senolytics: No human combination studies. Adding other cell-killing agents may add toxicity; this is a theoretical concern.
• Cancer therapies: Mouse studies altered responses to chemotherapy or radiation. Human combinations and treatment timing are untested.
• Anticoagulants: General injection-related bleeding concern, especially with muscle injections. No FOXO4-DRI drug interaction has been established.

Product quality risks

• No independent peer-reviewed test-purchase study of online FOXO4-DRI products was found.
• Online injectable peptides may have wrong ingredients, wrong amounts, solvents, particles, microbes or endotoxin.
• Indirect evidence: three online semaglutide samples had 7.7%-14.37% purity and detectable endotoxin. These were not FOXO4-DRI.
• An HPLC purity percentage alone does not prove identity, vial content, sterility or freedom from endotoxin.